Division of Sleep Medicine, University of North Dakota School of Medicine - Sanford Health, Fargo, North Dakota.
Department of Internal Medicine, Wayne State University, Detroit, Michigan.
J Clin Sleep Med. 2019 Jul 15;15(7):1037-1050. doi: 10.5664/jcsm.7890.
Sleep-related breathing disorders are very common and highly associated with many comorbid diseases. They have many metabolic consequences that impact appetite, energy expenditure, and systemic inflammation. These consequences are mediated through peptides (eg, ghrelin, leptin, adiponectin, resistin, apelin, obestatin, and neuropeptide Y).
We searched the literature (PubMed) for sleep-disordered breathing (SDB) and metabolic peptides and included 15, 22, 14, 4 and 2 articles for ghrelin, leptin, adiponectin, resistin, and apelin respectively.
Our review of the published literature suggests that leptin levels seem to correlate with body mass index and adiposity rather than obstructive sleep apnea. Conversely, levels of adiponectin and ghrelin are influenced by obstructive sleep apnea alone. Finally, resistin and apelin seem to be not correlated with obstructive sleep apnea. Regarding positive airway pressure (PAP) impact, it seems that PAP therapy affected the levels of these peptides (mainly ghrelin).
There is significant controversy in the literature regarding the impact of SDB and PAP therapy on these metabolic peptides. This could be due to the lack of randomized clinical trials and the variability of the methodology used in these studies. Further research is needed to assess the impact of SDB and PAP therapy on the levels of these peptides and whether this impact is also related to body mass index and body fat composition.
睡眠相关呼吸障碍非常常见,与许多合并症高度相关。它们有许多代谢后果,影响食欲、能量消耗和全身炎症。这些后果是通过肽(如 ghrelin、瘦素、脂联素、抵抗素、apelin、obestatin 和神经肽 Y)介导的。
我们搜索了关于睡眠呼吸障碍(SDB)和代谢肽的文献(PubMed),并分别纳入了 15、22、14、4 和 2 篇关于 ghrelin、leptin、adiponectin、resistin 和 apelin 的文章。
我们对已发表文献的综述表明,瘦素水平似乎与体重指数和肥胖程度相关,而与阻塞性睡眠呼吸暂停无关。相反,脂联素和 ghrelin 的水平仅受阻塞性睡眠呼吸暂停的影响。最后,抵抗素和 apelin 似乎与阻塞性睡眠呼吸暂停无关。关于正压通气(PAP)的影响,似乎 PAP 治疗会影响这些肽的水平(主要是 ghrelin)。
关于 SDB 和 PAP 治疗对这些代谢肽的影响,文献中存在很大争议。这可能是由于缺乏随机临床试验以及这些研究中使用的方法学的可变性。需要进一步研究来评估 SDB 和 PAP 治疗对这些肽水平的影响,以及这种影响是否也与体重指数和体脂肪组成有关。